Clinical trials: Double-blind Design
Angiofibroma of Face, Tuberous Sclerosis
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and 0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the treatment of cutaneous angiofibromas in pediatric…
- Trial name
- NCT03363763
- Testing
- Sirolimus 0.2%, Sirolimus 0.4%
- Where
- 8 sites in United States, China
- Volunteers
- 24 people
- Sponsor
- Aucta Pharmaceuticals, Inc
Randomized, Double-blind
Phase Three Clinical Trials of Trivalent Rotavirus Genetic Reassortment Vaccine
Assessment and evaluation the rotavirus gastroenteritis prevention effect and severe rotavirus diarrhea reducing effectiveness of human body, which inoculate trivalent rotavirus genetic reassortment vaccine.
- Conditions
- Randomized, Double-blind, Placebo Control Design
- Trial name
- NCT01738074
- Testing
- trivalent rotavirus genetic reassortment vaccine
- Volunteers
- 10,020 people, healthy volunteers welcome
- Sponsor
- Center for Disease Control and Prevention, Henan Province
Epidermylosis Bullosa
Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With Epidermolysis Bullosa
Randomised Double blind placebo controlled cross over design study of the efficacy of morphine for inflammatory pain in children with Epidermolysis Bullosa
- Trial name
- NCT00231517
- Testing
- topical opiod, morphine sulphate in intrasite gel
- Where
- United Kingdom
- Sponsor
- Institute of Child Health
Rotavirus Gastroenteritis
The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)
The Phase I clinical trial of the oral hexavalent reassortant rotavirus attenuated live vaccine (Vero Cells) will be conducted in a population ranging from 6 weeks to 59 years of age.
- Trial name
- NCT06950645
- Testing
- Oral hexavalent reassortant rotavirus attenuated live vaccine
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Exercise Induced Asthma
Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)
The purpose of this study is to determine the effect of four weeks of treatment with two investigational drugs (oral versus inhaled administration) plus an inhaled medication in the treatment of airway constriction brought on by…
- Trial name
- NCT00127166
- Testing
- Montelukast sodium, Salmeterol xinafoate, Fluticasone propionate
- Volunteers
- 154 people
- Sponsor
- Organon and Co
Resistant Epilepsy, Drug, Adolescent Epilepsy
Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies
EudraCT: 2018-003887-29 Objective:To evaluate the safety and efficacy of: MGCND00EP1 from MGC PHARMACEUTICALS d.o.o. Study Design: Randomized, double blind, placebo controlled parallel grouped study Sample Size: 103 subjects…
- Conditions
- Resistant Epilepsy, Drug, Adolescent Epilepsy, Children Epilepsy, Children and Adolescents With Resistant Epilepsies
- Trial name
- NCT04406948
- Testing
- MGCND00EP1, ECG, EEG
- Where
- 2 sites in Israel, Slovenia
- Sponsor
- MGC Pharmaceuticals d.o.o
Croup
Efficacy of Nebulized Beclomethasone Dipropionate (BDP) in the Treatment of Moderate Croup
Acute laryngotracheobronchitis, better known as croup, is one of the common respiratory complaints among children and the most common cause of airway obstruction in children aged six months to six years.
- Trial name
- NCT00938353
- Testing
- beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml
- Where
- Italy
- Volunteers
- 6 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Plaque Psoriasis
A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and a Placebo in patients with moderate to severe scalp psoriasis.
- Trial name
- NCT02413229
- Testing
- DSXS1411
- Volunteers
- 151 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Myopia
Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With Myopia
This study was to evaluate the superiority of the myopia progression control effect in the treatment group compared with the control group, evaluated by the change in spherical equivalent (SE) after 12 months of administration of…
- Trial name
- NCT07790640
- Testing
- CTO0308
- Where
- South Korea
- Volunteers
- 351 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Infections, Streptococcal
A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study
Evaluate lot-to-lot consistency, safety and reactogenicity of 3 doses of GSK Biologicals' 10-valent pneumococcal conjugate vaccine and non-inferiority with respect to Prevenar.
- Trial name
- NCT00307554
- Testing
- Pneumococcal (vaccine)
- Where
- 35 sites in Finland, France and 1 more
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acne Vulgaris
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.
- Trial name
- NCT05550337
- Testing
- Trifarotene 0.005 % Topical Cream, AKLIEF®
- Where
- 14 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Hand, Foot and Mouth Disease
Clinical Trial of Enterovirus 71（EV71） Inactivated Vaccine in Children Aged 36-71 Months
The purpose of this study is to evaluate the non-inferiority of experimental EV71 vaccine compared to the control EV71 vaccine in children aged 36-71 months, to evaluate the non-inferiority of EV71 vaccine used in children aged…
- Trial name
- NCT03909074
- Testing
- 36-71 months old children-experimental EV71 vaccine., 36-71 months old children-control EV71 vaccine., 6-35 months old children-experimental EV71 vaccine.
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd